

1/39




Figure 1

2/39




Figure 2

3/39




Figure 3




Figure 4




Figure 5




Figure 6

7/39




Figure 7

8/39




Figure 8

9/39




Figure 9

10/39





Figure 10

11/39





Figure 11


12/39

24 Hours Incubation of aptamers in Room Temperature and 37°C



Lane 1: 100 bp DNA Ladder
Lane 2: B66 (0 Hour) 400 ng/well
Lane 3: N66 (0 Hour) 400 ng/well
Lane 4: B66 (24 Hours, RT) 400 ng/well
Lane 5: N66 (24 Hours, RT) 400 ng/well
Lane 6: B66 (24Hours, 37°C) 400 ng/well
Lane 7: N66 (24 Hours, 37°C) 400 ng/well

100 Hours Incubation of aptamers in Room Temperature and 37°C



Lane 1: 100 bp DNA Ladder
Lane 2: B66 (0 Hour) 400 ng/well
Lane 3: N66 (0 Hour) 400 ng/well
Lane 4: B66 (100 Hours, RT) 400 ng/well
Lane 5: N66 (100 Hours, RT) 400 ng/well
Lane 6: B66 (100 Hours, 37°C) 400 ng/well
Lane 7: N66 (100 Hours, 37°C) 400 ng/well

Figure 12

13/39




Figure 13

14/39

Evaluation of WNDIII aptamers for diagnostic and therapeutic application





Figure 14


15/39



Lane 1: Ladder
Lane 2: E.coli BL21 DE3 Uninduced
Lane 3: E.coli BL21 DE3 Induced
Lane 4: E. coli BL21 DE3 induced
Lane 5: E.coli K12 AVB-100 Uninduced
Lane 6: E.coli K12 AVB-100 Induced
Lane 7: E.coli K12 AVB-100 induced

Figure 15

16/39




SAMPLE 1, 2, 3- FPLC purified fractions from 1 hour Invitro Biotinylation sample
SAMPLE 4, 5, 6- FPLC purified fractions from overnight Invitro Biotinylation sample

Figure 16

17/39


Streptavidin coated magnetic beads

Bc-Mag from bioclone



Elution of the protein from the bead is using 0.1 M glycine

UBN-MBP, BN-MPB, WNDIII Purified (No BAP), BN-WNDIII



Confirmation of Biotinylation for WNDIII using Bc-Mag

Figure 17

18/39




Figure 18

19/39




Figure 19

20/39




Figure 20

21/39




Figure 21

22/39




Figure 22

23/39




Figure 23

24/39




Figure 24

25/39




Figure 25




Figure 26

27/39




Figure 27

28/39




Figure 28

29/39




Figure 29

30/39




Figure 30

31/39




Figure 31

32/39




Figure 32

33/39




Figure 33

34/39




Figure 34

35/39





Figure 35



Modified Aptamers (Adaptamer Solutions)

Figure 36

37/39




Figure 37

38/39




Figure 38

39/39

Evaluation of DENV2 DIII aptamers for diagnostic and therapeutic application




Figure 39